Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

93 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to enroll pre-liver transplant patients who will be vaccinated with either the novel adjuvanted HBV vaccine or double doses of Engerix™-B. The immunogenicity and safety of the novel adjuvanted vaccine will be compared to Engerix™-B as the control vaccine

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype

NCT00697749

Hepatitis B

COMPLETED PHASE3

Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y

NCT00698061

Hepatitis B

COMPLETED PHASE3

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

NCT00697853

Hepatitis B

COMPLETED PHASE2

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y

NCT00698555

Hepatitis B

COMPLETED PHASE2

Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control

NCT00697866

Hepatitis B

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Group Type EXPERIMENTAL

HBV-MPL vaccine 208129

Intervention Type BIOLOGICAL

2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection

Group B

Group Type ACTIVE_COMPARATOR

Engerix™-B

Intervention Type BIOLOGICAL

3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HBV-MPL vaccine 208129

2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection

Intervention Type BIOLOGICAL

Engerix™-B

3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HBV-MPL vaccine 208129

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A male or female ≥ 18 years of age at the time of the first vaccination.
* Written informed consent obtained from the subject.
* Seronegative for anti-HBs-antibodies, anti-HBc-antibodies \& HBsAg.
* If the subject is female, she must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.
* Documented case of liver failure, such that the patient will require an eventual liver transplant

Exclusion Criteria

* Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine.
* Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine and ending 30 days after.
* Previous vaccination against hepatitis B (whether or not a non-responder to vaccination).
* Previous vaccination with an adjuvant system containing MPL®.
* History of hepatitis B infection.
* Known exposure to hepatitis B virus within 6 weeks.
* Previously confirmed human immunodeficiency virus (HIV) infection.
* A family history of congenital or hereditary immunodeficiency.
* Immunosuppression caused by the administration of parenteral steroids or chemotherapy.
* Suspected or confirmed multiple sclerosis in the subject (applicable to Centres 011, 012, 013 and 014/ France only).
* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
* Acute, intercurrent disease at the time of enrollment.
* Oral/axillary temperature of ≥ 37.5°C (≥ 99.5°F).
* Administration of immunoglobulins and/or any blood products within one month preceding the first dose of study vaccine or planned administration/ administration during the study period.
* Pregnant or lactating female

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No